DGIdb - PICTILISIB Drug Record

PICTILISIB chembl:CHEMBL521851 Antineoplastic

Alternate Names:

GDC 0941
CDC-0941
PICTILISIB
RG-7321
GDC-0941

Drug Info:

Notes	pan-PI3K inhibitor
Drug Class	Kinase Inhibitors

(5 More Sources)

Publications:

Arjumand et al., 2016, Phosphatidyl inositol-3 kinase (PIK3CA) E545K mutation confers cisplatin resistance and a migratory phenotype in cervical cancer cells., Oncotarget
Weigelt et al., 2013, PI3K pathway dependencies in endometrioid endometrial cancer cell lines., Clin. Cancer Res.
Spoerke et al., 2016, Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant., Nat Commun
Zheng et al., 2014, More antitumor efficacy of the PI3K inhibitor GDC-0941 in breast cancer with PIK3CA mutation or HER2 amplification status in vitro., Pharmazie
Hoeflich et al., 2012, Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition., Cancer Res.
Nacht M et al., 2013, Discovery of a potent and isoform-selective targeted covalent inhibitor of the lipid kinase PI3Kα., J Med Chem
Herrera-Abreu et al., 2016, Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer., Cancer Res.
Beaver et al., 2013, PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system., Clin. Cancer Res.
Spoerke et al., 2012, Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models., Clin. Cancer Res.
Haagensen et al., 2013, The enhanced in vivo activity of the combination of a MEK and a PI3K inhibitor correlates with [18F]-FLT PET in human colorectal cancer xenograft tumour-bearing mice., PLoS ONE
Potter et al., 2016, Inhibition of PI3K/BMX Cell Survival Pathway Sensitizes to BH3 Mimetics in SCLC., Mol. Cancer Ther.
Stratikopoulos et al., 2015, Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy., Cancer Cell
Le et al., 2016, Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer., Cancer Discov
de Lint et al., 2016, Sensitizing Triple-Negative Breast Cancer to PI3K Inhibition by Cotargeting IGF1R., Mol. Cancer Ther.
Packer et al., 2017, PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2(mutant) Endometrial Cancers., Mol. Cancer Ther.
Van Allen et al., 2014, The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma., Cancer Discov
Herkert et al., 2016, Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition., Cancer Res.
Hoeflich et al., 2009, Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression., Cancer Res.
Choong et al., 2013, Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors., J. Cell. Mol. Med.
Qian et al., 2012, Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling., Clin. Cancer Res.
Mahoney et al., 2009, LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition., Br. J. Cancer
Hayes et al., 2016, Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression., Cancer Cell
Hofmann et al., 2012, K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo., PLoS ONE
Utermark et al., 2012, The p110α and p110β isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis., Genes Dev.
Berger et al., 2014, Oncogenic RIT1 mutations in lung adenocarcinoma., Oncogene
Cheng et al., 2014, A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition., Cancer Res.
Vlietstra et al., 1998, Frequent inactivation of PTEN in prostate cancer cell lines and xenografts., Cancer Res.
Yang et al., 2016, Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha-Positive, PIK3CA-Mutant Breast Cancer., Clin. Cancer Res.

PICTILISIB RIT1

Interaction Score: 1.89

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24469055

Sources:
CIViC
PICTILISIB MPL

Interaction Score: 0.34

Interaction Types & Directionality:

n/a

Interaction Info:

Response Type sensitive

combination therapy GDC-0941 + Ruxolitinib

Indication/Tumor Type Advanced Solid Tumor

PMIDs:
24251790

Sources:
JAX-CKB
PICTILISIB PIK3CA

Interaction Score: 0.26

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

combination therapy BGJ398 + GDC-0941

combination therapy GDC-0941 + Linsitinib

combination therapy GDC-0941 + NVP-AEW541

PMIDs:
27489350 23674493 27174596 24601221 22084396 23360348 27020857 23888070 23136191 24339963 27197306 26058079 27604488 27196766 28119489

Sources:
DTC JAX-CKB CIViC MyCancerGenome GuideToPharmacology ChemblInteractions
PICTILISIB PTEN

Interaction Score: 0.23

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy GDC-0941 + MS417

Indication/Tumor Type breast cancer

Response Type predicted – sensitive

PMIDs:
24265153 22693356 27020857 23136191 9661880 26058079 26577700 19276360 24322983 28119489 26733612

Sources:
JAX-CKB
PICTILISIB STK11

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type endometrial cancer

Response Type sensitive

Approval Status Preclinical

PMIDs:
24322983

Sources:
JAX-CKB
PICTILISIB RB1

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Palbociclib + GDC-0941

Indication/Tumor Type triple-receptor negative breast cancer

Response Type no benefit

PMIDs:
27020857

Sources:
JAX-CKB
PICTILISIB PIK3C2A

Interaction Score: 0.13

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
MyCancerGenome
PICTILISIB PIK3R6

Interaction Score: 0.12

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
MyCancerGenome
PICTILISIB PIK3R5

Interaction Score: 0.12

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction PI3-kinase class I inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
MyCancerGenome ChemblInteractions
PICTILISIB PIK3R4

Interaction Score: 0.12

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
MyCancerGenome
PICTILISIB PIK3C2B

Interaction Score: 0.12

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
MyCancerGenome
PICTILISIB PIK3R3

Interaction Score: 0.11

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction PI3-kinase class I inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
MyCancerGenome ChemblInteractions
PICTILISIB PIK3C2G

Interaction Score: 0.11

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
MyCancerGenome
PICTILISIB PIK3C3

Interaction Score: 0.11

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
MyCancerGenome
PICTILISIB PIK3R1

Interaction Score: 0.11

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction PI3-kinase class I inhibitor

PMIDs:
None found

Sources:
MyCancerGenome ChemblInteractions
PICTILISIB PIK3R2

Interaction Score: 0.1

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction PI3-kinase class I inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
MyCancerGenome ChemblInteractions
PICTILISIB PIK3CD

Interaction Score: 0.09

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

PMIDs:
None found

Sources:
MyCancerGenome GuideToPharmacology ChemblInteractions
PICTILISIB PIK3CB

Interaction Score: 0.09

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

PMIDs:
None found

Sources:
MyCancerGenome GuideToPharmacology ChemblInteractions
PICTILISIB KRAS

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type myelodysplastic/myeloproliferative neoplasm

Response Type sensitive

Approval Status Preclinical

PMIDs:
22084396 22693356 19165201 26725216 22952903

Sources:
JAX-CKB
PICTILISIB LRRK2

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PICTILISIB BRAF

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy GDC0879 + GDC-0941

Indication/Tumor Type melanoma

Response Type sensitive

PMIDs:
24265153 26577700 19276360

Sources:
JAX-CKB
PICTILISIB CDK7

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PICTILISIB FGFR2

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical - Cell culture

Response Type sensitive

PMIDs:
28119489

Sources:
JAX-CKB
PICTILISIB PIK3CG

Interaction Score: 0.05

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? True

Direct Interaction? False

Endogenous Drug? False

PMIDs:
None found

Sources:
MyCancerGenome GuideToPharmacology ChemblInteractions
PICTILISIB ERBB2

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Palbociclib + GDC-0941

Indication/Tumor Type Her2-receptor positive breast cancer

Response Type sensitive

PMIDs:
27020857 22802530

Sources:
JAX-CKB CIViC
PICTILISIB JAK2

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy GDC-0941 + Ruxolitinib

Indication/Tumor Type Advanced Solid Tumor

Response Type sensitive

PMIDs:
24251790

Sources:
JAX-CKB
PICTILISIB AKT1

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical - Cell culture

Response Type resistant

PMIDs:
27604488

Sources:
JAX-CKB
PICTILISIB MAPK8

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PICTILISIB CLK4

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PICTILISIB YES1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

MyCancerGenome: GDC-0941
- Version: 20-Jun-2017
Alternate Names:

GDC-0941 Development Name

Drug Info:

Drug Class Kinase Inhibitors

Notes pan-PI3K inhibitor

Publications:
DTC: PICTILISIB
- Version: 02-September-2020
Alternate Names:

CHEMBL521851 ChEMBL Drug ID

Drug Info:

Publications:

Nacht M et al., 2013, Discovery of a potent and isoform-selective targeted covalent inhibitor of the lipid kinase PI3Kα., J Med Chem

JAX-CKB: GDC-0941

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Le et al., 2016, Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer., Cancer Discov

Choong et al., 2013, Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors., J. Cell. Mol. Med.

Weigelt et al., 2013, PI3K pathway dependencies in endometrioid endometrial cancer cell lines., Clin. Cancer Res.

CIViC: PICTILISIB

Version: 14-September-2020

Alternate Names:

Drug Info:

Publications:

Utermark et al., 2012, The p110α and p110β isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis., Genes Dev.

Berger et al., 2014, Oncogenic RIT1 mutations in lung adenocarcinoma., Oncogene

Arjumand et al., 2016, Phosphatidyl inositol-3 kinase (PIK3CA) E545K mutation confers cisplatin resistance and a migratory phenotype in cervical cancer cells., Oncotarget

TALC: GDC-0941
- Version: 12-May-2016
Alternate Names:

GDC-0941 Primary Drug Name

GDC-0941 Drug Synonym

Drug Info:

Publications:
GuideToPharmacology: 178102309
- Version: 29-September-2020
Alternate Names:

PICTILISIB GuideToPharmacology Ligand Name

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL521851
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ClearityFoundationClinicalTrial: GDC-0941
- Version: 15-June-2013
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL521851
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:

Response Type	sensitive
combination therapy	GDC-0941 + Ruxolitinib
Indication/Tumor Type	Advanced Solid Tumor

combination therapy	BGJ398 + GDC-0941
combination therapy	GDC-0941 + Linsitinib
combination therapy	GDC-0941 + NVP-AEW541

combination therapy	GDC-0941 + MS417
Indication/Tumor Type	breast cancer
Response Type	predicted – sensitive

Indication/Tumor Type	endometrial cancer
Response Type	sensitive
Approval Status	Preclinical

combination therapy	Palbociclib + GDC-0941
Indication/Tumor Type	triple-receptor negative breast cancer
Response Type	no benefit

Mechanism of Interaction	PI3-kinase class I inhibitor
Direct Interaction	yes

Specific Action of the Ligand	Inhibition
Endogenous Drug?	False
Direct Interaction?	False

Indication/Tumor Type	myelodysplastic/myeloproliferative neoplasm
Response Type	sensitive
Approval Status	Preclinical

combination therapy	GDC0879 + GDC-0941
Indication/Tumor Type	melanoma
Response Type	sensitive

Evidence Type	Actionable
Approval Status	Preclinical - Cell culture
Response Type	sensitive

Direct Interaction?	True
Direct Interaction?	False
Endogenous Drug?	False

PICTILISIB Drug Record

PICTILISIB chembl:CHEMBL521851 Antineoplastic

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24469055

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info: Response Type sensitive combination therapy GDC-0941 + Ruxolitinib Indication/Tumor Type Advanced Solid Tumor

PMIDs: 24251790

Sources: JAX-CKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: combination therapy BGJ398 + GDC-0941 combination therapy GDC-0941 + Linsitinib combination therapy GDC-0941 + NVP-AEW541

PMIDs: 27489350 23674493 27174596 24601221 22084396 23360348 27020857 23888070 23136191 24339963 27197306 26058079 27604488 27196766 28119489

Sources: DTC JAX-CKB CIViC MyCancerGenome GuideToPharmacology ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info: combination therapy GDC-0941 + MS417 Indication/Tumor Type breast cancer Response Type predicted – sensitive

PMIDs: 24265153 22693356 27020857 23136191 9661880 26058079 26577700 19276360 24322983 28119489 26733612

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type endometrial cancer Response Type sensitive Approval Status Preclinical

PMIDs: 24322983

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Palbociclib + GDC-0941 Indication/Tumor Type triple-receptor negative breast cancer Response Type no benefit

PMIDs: 27020857

Sources: JAX-CKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: None found

Sources: MyCancerGenome

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: None found

Sources: MyCancerGenome

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction PI3-kinase class I inhibitor Direct Interaction yes

PMIDs: None found

Sources: MyCancerGenome ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: None found

Sources: MyCancerGenome

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: None found

Sources: MyCancerGenome

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction PI3-kinase class I inhibitor Direct Interaction yes

PMIDs: None found

Sources: MyCancerGenome ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: None found

Sources: MyCancerGenome

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: None found

Sources: MyCancerGenome

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction PI3-kinase class I inhibitor

PMIDs: None found

Sources: MyCancerGenome ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction PI3-kinase class I inhibitor Direct Interaction yes

PMIDs: None found

Sources: MyCancerGenome ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Specific Action of the Ligand Inhibition Endogenous Drug? False Direct Interaction? False

PMIDs: None found

Sources: MyCancerGenome GuideToPharmacology ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Specific Action of the Ligand Inhibition Endogenous Drug? False Direct Interaction? False

PMIDs: None found

Sources: MyCancerGenome GuideToPharmacology ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type myelodysplastic/myeloproliferative neoplasm Response Type sensitive Approval Status Preclinical

PMIDs: 22084396 22693356 19165201 26725216 22952903

Interaction Types & Directionality:

n/a

PMIDs:
24469055

Sources:
CIViC

Interaction Types & Directionality:

n/a

Interaction Info:

Response Type sensitive

combination therapy GDC-0941 + Ruxolitinib

Indication/Tumor Type Advanced Solid Tumor

PMIDs:
24251790

Sources:
JAX-CKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

combination therapy BGJ398 + GDC-0941

combination therapy GDC-0941 + Linsitinib

combination therapy GDC-0941 + NVP-AEW541

PMIDs:
27489350 23674493 27174596 24601221 22084396 23360348 27020857 23888070 23136191 24339963 27197306 26058079 27604488 27196766 28119489

Sources:
DTC JAX-CKB CIViC MyCancerGenome GuideToPharmacology ChemblInteractions

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy GDC-0941 + MS417

Indication/Tumor Type breast cancer

Response Type predicted – sensitive

PMIDs:
24265153 22693356 27020857 23136191 9661880 26058079 26577700 19276360 24322983 28119489 26733612

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type endometrial cancer

Response Type sensitive

Approval Status Preclinical

PMIDs:
24322983

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Palbociclib + GDC-0941

Indication/Tumor Type triple-receptor negative breast cancer

Response Type no benefit

PMIDs:
27020857

Sources:
JAX-CKB

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
None found

Sources:
MyCancerGenome

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
None found

Sources:
MyCancerGenome

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction PI3-kinase class I inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
MyCancerGenome ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
None found

Sources:
MyCancerGenome

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
None found

Sources:
MyCancerGenome

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction PI3-kinase class I inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
MyCancerGenome ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
None found

Sources:
MyCancerGenome

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
None found

Sources:
MyCancerGenome

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction PI3-kinase class I inhibitor

PMIDs:
None found

Sources:
MyCancerGenome ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction PI3-kinase class I inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
MyCancerGenome ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

PMIDs:
None found

Sources:
MyCancerGenome GuideToPharmacology ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

PMIDs:
None found

Sources:
MyCancerGenome GuideToPharmacology ChemblInteractions

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type myelodysplastic/myeloproliferative neoplasm

Response Type sensitive

Approval Status Preclinical

PMIDs:
22084396 22693356 19165201 26725216 22952903

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy GDC0879 + GDC-0941

Indication/Tumor Type melanoma

Response Type sensitive

PMIDs:
24265153 26577700 19276360

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a